journal article·2021-12-22

Engineered Hydroxyapatite Nanoadjuvants with Controlled Shape and Aspect Ratios Reveal Their Immunomodulatory Potentials

Lei Zhang, Zhihui Liang, Chen Chen, Xuecheng Yang, Duo Fu, Hang Bao, Min Li, Shuting Shi, Ge Yu, Yixuan Zhang, Caiqiao Zhang, Weiting Zhang, Changying Xue, Bingbing Sun

ACS Applied Materials & Interfaces· Volume 13· Issue 50
Publisher page

Abstract

Hydroxyapatite (HAP) has been formulated as adjuvants in vaccines for human use. However, the optimal properties required for HAP nanoparticles to elicit adjuvanticity and the underlying immunopotentiation mechanisms have not been fully elucidated. Herein, a library of HAP nanorods and nanospheres was synthesized to explore the effect of the particle shape and aspect ratio on the immune responses in vitro and adjuvanticity in vivo. It was demonstrated that long aspect ratio HAP nanorods induced a higher degree of cell membrane depolarization and subsequent uptake, and the internalized particles elicited cathepsin B release and mitochondrial reactive oxygen species generation, which further led to pro-inflammatory responses. Furthermore, the physicochemical property-dependent immunostimulation capacities were correlated with their humoral responses in a murine hepatitis B surface antigen immunization model, with long aspect ratio HAP nanorods inducing higher antigen-specific antibody productions. Importantly, HAP nanorods significantly up-regulated the IFN-γ secretion and CD107α expression on CD8+ T cells in immunized mice. Further mechanistic studies demonstrated that HAP nanorods with defined properties exerted immunomodulatory effects by enhanced antigen persistence and immune cell recruitments. Our study provides a rational design strategy for engineered nanomaterial-based vaccine adjuvants.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, Dalian 116024, P. R. China

School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian 116024, P. R. China

School of Bioengineering, Dalian University of Technology, 2 Linggong Road, Dalian 116024, P. R. China

NCPC Genetech Biotechnology Co., Ltd., Shijiazhuang 050035, P. R. China

Funding

Central University Basic Research Fund of China · Natural Science Foundation of Liaoning Province · National Natural Science Foundation of China · Dalian Science and Technology Innovation Fund

References (70)

Show source-provided references
1. 10.1016/j.vaccine.2019.04.05510.1016/j.vaccine.2019.04.055 ↗
2. 10.1038/s41565-020-0739-910.1038/s41565-020-0739-9 ↗
3. 10.1016/j.coi.2017.07.01010.1016/j.coi.2017.07.010 ↗
4. 10.1016/j.coi.2017.06.00510.1016/j.coi.2017.06.005 ↗
5. 10.1016/j.biomaterials.2021.12096010.1016/j.biomaterials.2021.120960 ↗
6. 10.1038/s41541-018-0089-x10.1038/s41541-018-0089-x ↗
7. 10.3389/fimmu.2020.58983310.3389/fimmu.2020.589833 ↗
8. 10.1016/j.vaccine.2015.10.13210.1016/j.vaccine.2015.10.132 ↗
9. 10.1080/14760584.2017.135573310.1080/14760584.2017.1355733 ↗
10. 10.1080/14760584.2017.124448410.1080/14760584.2017.1244484 ↗
11. 10.1016/s0264-410x(96)00092-810.1016/s0264-410x(96)00092-8 ↗
12. 10.7774/cevr.2015.4.1.8810.7774/cevr.2015.4.1.88 ↗
13. 10.3109/1547691x.2013.77226710.3109/1547691x.2013.772267 ↗
14. 10.1128/cdli.9.5.1021-1024.200210.1128/cdli.9.5.1021-1024.2002 ↗
15. 10.1016/s0264-410x(97)00288-010.1016/s0264-410x(97)00288-0 ↗
16. 10.1128/cdli.7.6.899-903.200010.1128/cdli.7.6.899-903.2000 ↗
17. 10.1016/s0264-410x(97)00054-610.1016/s0264-410x(97)00054-6 ↗
18. 10.1016/j.biomaterials.2009.06.02310.1016/j.biomaterials.2009.06.023 ↗
19. 10.1016/j.vaccine.2015.11.05910.1016/j.vaccine.2015.11.059 ↗
20. 10.1016/j.colsurfb.2018.11.02610.1016/j.colsurfb.2018.11.026 ↗
21. 10.1039/c6cc02848a10.1039/c6cc02848a ↗
22. 10.1038/s41598-017-03086-010.1038/s41598-017-03086-0 ↗
23. 10.1021/acsnano.9b0127110.1021/acsnano.9b01271 ↗
24. 10.1039/c6tb01131d10.1039/c6tb01131d ↗
25. 10.1021/acsami.7b0581710.1021/acsami.7b05817 ↗
26. 10.1016/j.biomaterials.2016.01.02610.1016/j.biomaterials.2016.01.026 ↗
27. 10.1016/j.ceramint.2016.12.02210.1016/j.ceramint.2016.12.022 ↗
28. 10.1016/j.vaccine.2008.11.02910.1016/j.vaccine.2008.11.029 ↗
29. 10.1002/adma.20200421010.1002/adma.202004210 ↗
30. 10.1038/s41591-020-0753-310.1038/s41591-020-0753-3 ↗
31. 10.1016/j.jcrysgro.2012.09.01010.1016/j.jcrysgro.2012.09.010 ↗
32. 10.1002/smll.20140285910.1002/smll.201402859 ↗
33. 10.1016/j.biomaterials.2018.07.01210.1016/j.biomaterials.2018.07.012 ↗
34. 10.1016/j.biomaterials.2018.07.05810.1016/j.biomaterials.2018.07.058 ↗
35. 10.1002/jcp.2898710.1002/jcp.28987 ↗
36. 10.1080/0277224070180255910.1080/02772240701802559 ↗
37. 10.1021/acs.langmuir.9b0257810.1021/acs.langmuir.9b02578 ↗
38. 10.1161/01.str.30.1.17110.1161/01.str.30.1.171 ↗
39. 10.1016/s0306-4522(98)00065-710.1016/s0306-4522(98)00065-7 ↗
40. 10.1002/glia.2011210.1002/glia.20112 ↗
41. 10.1016/j.expneurol.2011.09.03010.1016/j.expneurol.2011.09.030 ↗
42. 10.1021/acsnano.6b0156010.1021/acsnano.6b01560 ↗
43. 10.1021/nn301211410.1021/nn3012114 ↗
44. 10.1021/nn200595c10.1021/nn200595c ↗
45. 10.1002/smll.20120196210.1002/smll.201201962 ↗
46. 10.1021/acsami.6b0609410.1021/acsami.6b06094 ↗
47. 10.1016/j.tiv.2005.06.03110.1016/j.tiv.2005.06.031 ↗
48. 10.1016/0003-2697(67)90110-810.1016/0003-2697(67)90110-8 ↗
49. 10.1016/j.biomaterials.2008.09.00110.1016/j.biomaterials.2008.09.001 ↗
50. 10.1073/pnas.111776510910.1073/pnas.1117765109 ↗
51. 10.1038/nature0966310.1038/nature09663 ↗
52. 10.1126/science.115699510.1126/science.1156995 ↗
53. 10.1039/c9nr03756j10.1039/c9nr03756j ↗
54. 10.4049/jimmunol.181.7.454510.4049/jimmunol.181.7.4545 ↗
55. 10.1021/acsnano.8b0108610.1021/acsnano.8b01086 ↗
56. 10.1016/j.vaccine.2008.11.07810.1016/j.vaccine.2008.11.078 ↗
57. 10.1016/j.vaccine.2003.10.02310.1016/j.vaccine.2003.10.023 ↗
58. 10.1016/j.csbj.2018.11.00610.1016/j.csbj.2018.11.006 ↗
59. 10.1016/j.vaccine.2015.08.00610.1016/j.vaccine.2015.08.006 ↗
60. 10.1016/j.jconrel.2020.05.04210.1016/j.jconrel.2020.05.042 ↗
61. 10.1002/art.2418510.1002/art.24185 ↗
62. 10.1038/s41598-020-65422-110.1038/s41598-020-65422-1 ↗
63. 10.1016/j.biomaterials.2021.12067410.1016/j.biomaterials.2021.120674 ↗
64. 10.1021/nn404211j10.1021/nn404211j ↗
65. 10.1016/j.vaccine.2014.04.04310.1016/j.vaccine.2014.04.043 ↗
66. 10.1073/pnas.142292311210.1073/pnas.1422923112 ↗
67. 10.1021/nl101140t10.1021/nl101140t ↗
68. 10.1039/c8cs00028j10.1039/c8cs00028j ↗
69. 10.1016/j.biomaterials.2015.03.01310.1016/j.biomaterials.2015.03.013 ↗
70. 10.1021/nn305700510.1021/nn3057005 ↗